Rossana Ruiz

Employment

• Oncosalud
  2017 - Present
• Massachusetts General Hospital Research Fellow
  2015 - 2016
• Instituto Nacional de Enfermedades Neoplásicas Attending Physician
  2014 - Present

Education

• Universidad Peruana Cayetano Heredia Oncologist
  2010 - 2014
• Universidad de San Martín de Porres Facultad de Medicina Humana MD
  2002 - 2009

Projects & Funding

Projects & funding information is unavailable.

Publications (21)

• Update in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Best Choices
  Kátia Roque, Rossana Ruiz, Luis A. Mas +4 more
  Cancers 2023 DOI: 10.3390/cancers15184547
  +Save
• ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer
  Critical Reviews in Oncology/Hematology 2019 DOI: 10.1016/j.critrevonc.2019.02.006
  +Save
• Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP)
  Thoracic Cancer 2019 DOI: 10.1111/1759-7714.13272
  +Save
• Lung Cancer in the Young
  Lung 2019 DOI: 10.1007/s00408-019-00294-5
  +Save
• Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?
  ESMO open 2018 DOI: 10.1136/esmoopen-2018-000344
  +Save
• Potential new biomarkers for squamous carcinoma of the uterine cervix
  ESMO Open 2018 DOI: 10.1136/esmoopen-2018-000352
  +Save
• Neoadjuvant trials can accelerate research on novel systemic treatment modalities in cancer of the uterine cervix.
  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2017 DOI: 10.1016/j.ejso.2017.09.018
  +Save
• Epidemiology and pathophysiology of pregnancy-associated breast cancer: A review.
  Breast (Edinburgh, Scotland) 2017 DOI: 10.1016/j.breast.2017.07.008
  +Save
• Improving access to high-cost cancer drugs in Latin America: Much to be done.
  2017 DOI: 10.1002/cncr.30549
  +Save
• Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key
  World Journal of Clinical Oncology 2017 DOI: 10.5306/wjco.v8.i6.437
  +Save
• Primary cutaneous T-cell lymphoma: experience from the Peruvian National Cancer Institute.
  Anais brasileiros de dermatologia 2017 DOI: 10.1590/abd1806-4841.20176825
  +Save
• [Clinical-pathological features and survival in young women with cervical cancer: a retrospective analysis from the instituto nacional de enfermedades neoplásicas].
  Revista peruana de medicina experimental y salud publica 2017 DOI: 10.17843/rpmesp.2017.342.2653
  +Save
• Current and emerging therapies of HER2-positive metastatic breast cancer
  The Breast 2016 DOI: 10.1016/j.breast.2016.07.026
  +Save
• End-of-Life Care in Latin America
  Journal of Global Oncology 2016 DOI: 10.1200/jgo.2016.005579
  +Save
• Cáncer colorrectal en los jóvenes: factores pronósticos y características clínico patológicas en un instituto del cáncer de Perú
  Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru 2016
  +Save
• Cáncer colorrectal en los jóvenes: factores pronósticos y características clínico patológicas en un instituto del cáncer de Perú.
  2016
  +Save
• Entinostat (SNDX-275) for the treatment of non-small cell lung cancer
  Expert Opinion on Investigational Drugs 2015 DOI: 10.1517/13543784.2015.1056779
  +Save
• Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
  2015 DOI: 10.1517/13543784.2015.1096344
  +Save
• Immunotherapeutic Agents in Non-small-cell Lung Cancer Finally Coming to the Front Lines
  Current Oncology Reports 2014 DOI: 10.1007/s11912-014-0400-6
  +Save
• Can We Improve the FIGO Risk Score? Developing the In-FIGO Score for Patients with Gestational Trophoblastic Neoplasia
  DOI: 10.20944/preprints202409.1575.v1
  +Save